Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea
Key facts
- Who runs it
- China Medical University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 45 people enrolled
- Started
- 5 Nov 2024
- Ended
- 22 Oct 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- Atomoxetine 80mg combined with oxybutynin 5mg
- Venlafaxine 37.5mg
- oxybutynin 5mg combined with trazodone 100mg
- Placebo
- Record updated
- 23 April 2026
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- apnea-hypopnea index ≥ 15 hr-¹
Who cannot take part
- current use of continuous positive airway pressure therapy
- use of drugs that might interact with the investigational medication or known to affect sleep during the trial or 1 month before the study
- the presence of pulmonary, cardiac, neurologic, or other active severe medical or psychiatric diseases
- known allergy to the investigational medication
- current smoking
- heavy alcohol drinking (male > 14 drinks and women >7 drinks per week)
- pregnant or lactating
- periodic limb movement index > 15hr-1
- the presence of sleep-related hypoventilation
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will conduct 3 intervention trials with 44 different participants in each trial, with 22 participants will undergo in-laboratory overnight polysomnograms (PSGs) at one night of medication intervention, and the other 22 at taking placebo (contained starch) 1 h before sleep. Three medication regimens will be tested: (1) atomoxetine 80mg combined with oxybutynin 5mg; (2) venlafaxine 37.5mg; and (3) oxybutynin 5mg combined with trazodone 100mg. Endotypic traits will be estimated using the Phenotyping Using Polysomnography method. The primary outcome is the change in apnea-hypopnea index, and secondary outcomes include endotypic traits and sleep parameters.
The 3 groups in the trial
- atomoxetine 80mg combined with oxybutynin 5mgTreatment being tested
Participants will receive atomoxetine 80mg combined with oxybutynin 5mg once (1 h before polysomnographic study).
Treatment: Atomoxetine 80mg combined with oxybutynin 5mg and Placebo
- venlafaxine 37.5mgTreatment being tested
Participants will receive venlafaxine 37.5mg once (1 h before polysomnographic study).
Treatment: Venlafaxine 37.5mg and Placebo
- oxybutynin 5mg combined with trazodone 100mgTreatment being tested
Participants will receive oxybutynin 5mg combined with trazodone 100mg once (1 h before polysomnographic study).
Treatment: oxybutynin 5mg combined with trazodone 100mg and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 April 2026